ID | 1031 |
Name of the vaccine | Td-pur |
Microbe | Bacteria |
Disease name | Diphtheria |
Name of bacteria | Corynebacterium diphtheriae |
Type of vaccine | Combination |
Nucleic acid content | DNA |
Age | From 5 years |
Description of the vaccine | Combination of tetanus toxoid and diphtheria toxoid. |
Name of the manufacturer | Novartis vaccine Diagnostics GmbH & Co. KG. |
Name of the manufacturing country | NA |
Year of manufacture | 2005 |
Clinical Phase status | Approved |
Bacterial strain | Gram-positive bacillus. |
Efficacy | NA |
Vaccine formulation | Whitish, turbid suspension |
Dosage | Primary Immunisation: Three doses.
Booster: At 10 year intervals. |
Mechanism of action | NA |
Route of administration | Intramuscular |
Indications | Immunisation against tetanus and diphtheria. |
Export | Marketing Authorisation Holder : Biogenetech Co., Ltd., Thailand |
Approval | Thailand FDA |
Adjuvant | Aluminium hydroxide |
Repurposing | For tetanus. |
Side effects of vaccine | Erythema , swelling, pain, induration, itching, myalgia, headache |
Post vaccination | NA |
Dose type | Combination (4 doses) |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NA |
Reference | https://www.fda.moph.go.th/sites/drug/Summary/2C_9_48_Td%20pur.pdf |
Other name | NA |
Additional Links | NA
|